F8 and hemophilia: During the period of 14 years, these 155 inhibitors represented 25.5% (155/608) of all FVIII/IX inhibitors reported to EUHASS, the other inhibitors were reported in patients with severe hemophilia and were presented in previous analyses and the EUHASS annual reports from 2019 to 2022 [3,10].